Putting Science to Work

In the News

  • Syngene International net surges by 18.5% in Q4 to Rs. 100 crore, bonus shares in ratio of 1:1

    Pharmabiz- 30/04/2019. During the quarter, Syngene and the Government of India's Biotechnology Industry Research Assistance Council (BIRAC) collaborated to set up a Centre for Advanced Protein Studies (CAPS) at its Bengaluru campus.


  • Syngene International wins CMO Leadership Award 2019

    BioSpectrum- 22/03/2019. Syngene was successfully rated across the six categories - Capabilities, Compatibility, Expertise, Quality, Reliability and Service – that were used to gauge the eventual winner.


  • Syngene Q3 net profit up 6 pc to Rs 87 cr

    Business Standard- 22/01/2019. Consolidated total revenue of the company stood at Rs 484.4 crore for the quarter under consideration as against Rs 399.3 crore for the same period a year ago.


  • First of its kind symposium on Next Gen Ab Platforms

    Biospectrum- 06/12/2018. The symposium was hosted under the aegis of “INNO”, a platform that aims to facilitate knowledge-sharing among scientists across industry and academia.


  • Syngene International net up by 1.7% in Q2

    PharmaBiz- 25/10/2018. Both our Discovery Services and Dedicated Centre verticals performed well, with the later benefiting from expansions announced earlier in the year of our collaboration with Baxter.


  • Syngene International Q1 net profit up 6% at Rs 66 crore

    PharmaBiz- 26/07/2018. The quarter saw good performance within biologics manufacturing, discovery services and chemical development services as well as a benefit from improved FX rates.


  • Syngene expands agreement with Baxter

    India Infoline- 23/07/2018. Syngene and Baxter originally established the Baxter Global Research Center in 2013. The duration of the new agreement has now been extended until 2024.


  • Artelo Biosciences Enters Into Global R&D Partnership With Syngene International And Aptus Clinical For The Clinical Development Of ART27.13 In Oncology

    Cision PR Newswire- 12/06/2018. As part of the agreement, Syngene will be the discovery and development partner providing a pre-clinical data package to support the advancement of ART27.13 for anti-cancer indications.


  • Syngene teams with immuno-oncology firm to provide greater value-added services

    Out Sourcing Pharma- 04/06/2018. As per the partnering agreement, Syngene will screen target antigens Zumutor’s human antibody libraries to identify and characterize novel antibody clones- which it will further develop towards novel biotherapeutics programs.


  • An Exclusive Interview with Jonathan Hunt – CEO, Syngene International, India by Pharma Boardroom

    Pharma Boardroom- 24/05/2018. Syngene International, one of the fastest growing and leading contract research and manufacturing organizations in the world, discusses the company’s unique ecosystem of innovation...


Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget